Eupraxia Pharmaceuticals Files 6-K Report
Ticker: EPRX · Form: 6-K · Filed: May 21, 2024 · CIK: 1581178
Sentiment: neutral
Topics: filing, regulatory-update, foreign-private-issuer
Related Tickers: EPRX
TL;DR
Eupraxia Pharma (EPRX) filed a 6-K, check the press release for news.
AI Summary
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on May 21, 2024, reporting information as a foreign private issuer. The filing includes Exhibit 99.1, a press release dated May 21, 2024. The company is incorporated in Canada and its principal executive offices are located in Victoria, British Columbia.
Why It Matters
This filing provides an update on Eupraxia Pharmaceuticals' regulatory reporting, indicating ongoing operations and disclosures to the SEC.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) that typically contains press releases or other periodic information, not significant financial events.
Key Players & Entities
- EUPRAXIA PHARMACEUTICALS INC. (company) — Registrant
- May 21, 2024 (date) — Filing date and press release date
- Bruce Cousins (person) — Signatory for the filing
- 201-2067 Cadboro Bay Road, Victoria, British Columbia, Canada V8R 5G4 (location) — Principal executive offices
FAQ
What type of report is Eupraxia Pharmaceuticals Inc. filing?
Eupraxia Pharmaceuticals Inc. is filing a Form 6-K, which is a Report of Foreign Private Issuer.
What is the filing date of this Form 6-K?
The Form 6-K was filed on May 21, 2024.
What is included as part of this report?
Exhibit 99.1, a Press Release dated May 21, 2024, is included as part of this report.
Where are Eupraxia Pharmaceuticals Inc.'s principal executive offices located?
The company's principal executive offices are located at 201-2067 Cadboro Bay Road, Victoria, British Columbia, Canada V8R 5G4.
Who signed this Form 6-K on behalf of Eupraxia Pharmaceuticals Inc.?
Bruce Cousins signed the Form 6-K on behalf of Eupraxia Pharmaceuticals Inc.
Filing Stats: 169 words · 1 min read · ~1 pages · Grade level 14.2 · Accepted 2024-05-21 17:05:36
Filing Documents
- form6k.htm (6-K) — 11KB
- ex991.htm (EX-99.1) — 23KB
- logo.jpg (GRAPHIC) — 23KB
- 0001279569-24-000644.txt ( ) — 68KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Eupraxia Pharmaceuticals Inc. Date: May 21, 2024 By: /s/ Bruce Cousins Name: Bruce Cousins Title: President and Chief Financial Officer